Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm

[{"selector":"#anim-04e7c120-828e-441d-bc5d-fe8a8077896a","keyframes":{"opacity":[0,1]},"delay":0,"duration":1200,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6c26c26d-0faf-4d7c-8c91-c546e132a1b4","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-4edc4676-3f00-405d-a0ea-4d7ccb0319c2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 1. Sanofi and AstraZeneca's Phase IIIb HARMONIE trial demonstrates that nirsevimab reduces hospitalizations due to respiratory syncytial virus (RSV) by 83.21% and severe RSV-related lower respiratory tract disease (LRTD) by 75.71% in infants under 12 months. Gray Frame Corner Gray Frame Corner

2. The RSV antibody candidate also lessens the overall incidence of all-cause LRTD hospitalization by 58.04%.

[{"selector":"#anim-ace77013-2d50-4c21-8d27-d872c77fdc8d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

3. HARMONIE is a large-scale European study evaluating the efficacy of a single nirsevimab dose at eliciting RSV protection, as compared with no immunization, with an estimated enrollment of 22,000 infants.

[{"selector":"#anim-cea316ff-00ad-43a1-9749-fa98b4406ea1","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-29c6dc19-e97f-4771-a7dd-04bad2eab013","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 4. Nirsevimab consistently demonstrated protection levels of around 80% against medically attended RSV infections across Phase III MELODY and Phase II/III MEDLEY trials and other Phase IIb data. Gray Frame Corner Gray Frame Corner

5. Pfizer's RSV hopeful Abrysvo will be reviewed by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on May 18.

[{"selector":"#anim-ae992781-0193-495e-a69b-0124fb7b0923","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-344cc8d4-1601-41bb-a73b-0df3c851f9b3","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 6. Pfizer's Phase III MATISSE trial demonstrates a vaccine efficacy rate of 66.7% against RSV-associated lower respiratory tract illness (LRTI) with two or more symptoms and 85.7% against severe LRTI. Gray Frame Corner Gray Frame Corner

7. The FDA will decide on Abrysvo's fate in the pediatric setting by August 2023.

[{"selector":"#anim-0eed6ea0-a1c8-4203-add9-24030badbfa2","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

8. GSK won the FDA's first approval for an RSV vaccine for older adults aged 60 years and above last week.

[{"selector":"#anim-4efc521d-67a4-492d-8e70-02cf52ee9712","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

[{"selector":"#anim-55aeef8e-d258-410b-838f-27de0a65bd4c","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] 9. GSK had to suspend three maternal trials due to safety concerns in February 2020, making Pfizer and Sanofi/AstraZeneca the frontrunners in the RSV vaccine race for kids. Gray Frame Corner Gray Frame Corner

10. Nirsevimab is an investigational long-acting antibody that induces passive immunity against RSV by binding to the part on the virus that it uses to attach to its target cells.

[{"selector":"#anim-7056a9ad-03ed-41b0-ab0e-a5588c94b89d","keyframes":{"opacity":[0,1]},"delay":0,"duration":2500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Gray Frame Corner Gray Frame Corner

Swipe up for more BIOMARKER news!

[{"selector":"#anim-3dc48596-930f-4508-86e2-1850bf4574ce","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] Learn more